The 80-week Lancet study enrolled 1,152 adults. Placebo lost 5.1%, and nearly half on the 12 mg dose lost at least 20%. The drug is still investigational.
Recap by typeshit. Full story at Medindia.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Another short teaser from the Medical Update interview series, this one on the pace of weight loss with GLP-1 drugs. The full episode is on Spotify.
A new episode of the In Discussion With series looks at the pace of weight loss on GLP-1 receptor agonists.
Loading…